Medicine and Dentistry
Overall Survival
100%
Malignant Neoplasm
93%
Surgery
87%
Oncology
75%
Colorectal Liver Metastasis
69%
Clinical Trial
44%
Chemoradiotherapy
44%
Arm
39%
Neoadjuvant Therapy
38%
Preoperative Chemotherapy
38%
Immunotherapy
35%
Recurrent Disease
34%
Cross Sectional Study
32%
Metastatic Carcinoma
30%
Systemic Therapy
28%
Biological Marker
27%
Immune Checkpoint Inhibitor
26%
Neoplasm
26%
Stomach Cancer
26%
Hepatocellular Carcinoma
26%
Rectum Cancer
26%
Esophageal Cancer
26%
Cholangiocarcinoma
26%
Biliary Tract Cancer
26%
Recurrence Free Survival
26%
Progression Free Survival
25%
Primary Tumor
24%
Colorectal Cancer
23%
Disease
22%
Cytotoxic Chemotherapy
21%
Hepatectomy
21%
Treatment Response
19%
Gastrointestinal Cancer
19%
Adjuvant Chemotherapy
18%
Pancreas Adenocarcinoma
17%
Cancer Cell
17%
Patient Referral
16%
Advanced Cancer
16%
Systematic Review
16%
Randomized Controlled Trial
15%
Randomized Clinical Trial
15%
Adenocarcinoma
15%
Proteinase Inhibitor
15%
Gemcitabine
15%
Colon Adenocarcinoma
15%
Bleeding
15%
Pancreas Cancer
15%
Hepatic Arterial Infusion
14%
Liver Metastasis
14%
Adverse Event
14%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
97%
Overall Survival
84%
Malignant Neoplasm
81%
Colorectal Liver Metastasis
66%
Neoplasm
53%
Liver Cell Carcinoma
39%
Recurrent Disease
36%
Systemic Treatment
34%
Metastatic Colorectal Cancer
32%
Stomach Cancer
31%
Colorectal Cancer
31%
Progression Free Survival
31%
Clinical Trial
28%
Fluorouracil
28%
Immunotherapy
27%
Irinotecan
26%
Esophagus Cancer
26%
Hepatitis C
26%
Biliary Tract Cancer
26%
Recurrence Free Survival
24%
Immune Checkpoint Inhibitor
23%
Metastasis
21%
Chemoradiation Therapy
18%
Pancreas Adenocarcinoma
18%
Adverse Event
18%
Cytotoxic Chemotherapy
17%
Primary Tumor
17%
Cross Sectional Study
16%
Pancreas Cancer
15%
Gemcitabine
15%
Folinic Acid
14%
HIV
13%
Paclitaxel
13%
Advanced Cancer
13%
Telaprevir
13%
Boceprevir
13%
Thromboembolism
13%
Rectum Cancer
13%
Docetaxel
13%
Hepatitis E
13%
Anticarcinogen
13%
Bevacizumab
13%
Erlotinib
13%
Esophageal Adenocarcinoma
13%
Sorafenib
13%
Colon Adenocarcinoma
13%
Hepatitis C Virus
13%
Drug Dose
13%
Peroperative Complication
13%
Celecoxib
13%
Keyphrases
Oncological Outcomes
39%
Systemic Treatment
35%
Chemotherapy
34%
Advanced or Metastatic
32%
Overall Survival
31%
Colorectal Liver Metastases
29%
Immune Checkpoint Inhibitors
29%
Phase II Study
28%
Repeat Hepatic Resection
26%
Irinotecan
26%
Hepatocellular Carcinoma
26%
5-fluorouracil (5-FU)
26%
Metastatic Colorectal Cancer (mCRC)
26%
Pancreatic Cancer
26%
Biliary Tract Cancer
26%
Human Epidermal Growth Factor Receptor 2 (HER2)
26%
Colorectal Cancer
23%
Response Rate
20%
Confidence Interval
18%
Preoperative Chemotherapy
18%
Median Overall Survival
17%
Phase II Trial
17%
Hazard Ratio
17%
HER2-positive
16%
Hepatitis C Virus Infection
16%
Neoadjuvant Therapy
16%
Gastric Cancer
15%
Referral Center
15%
Treatment Delay
15%
Tumor
15%
Treatment Response
14%
Phase I Trial
14%
Magnitude of Clinical Benefit Scale
13%
Progression-free Survival
13%
Malignant Colorectal Polyps
13%
Telaprevir
13%
Hepatectomy
13%
Survivability
13%
Oncology Trials
13%
Gastroesophageal Adenocarcinoma
13%
Advanced Esophageal Cancer
13%
Chemotherapy Delivery
13%
Boceprevir
13%
Novel Biomarkers
13%
Multidisciplinary Team Discussion
13%
Public Safety Net
13%
Metachronous Liver Metastasis
13%
Phospho-Akt
13%
MFOLFOX6
13%
Advanced Gastric Cancer
13%